Dr Reddy’s gets USFDA nod for Rituximab biosimilar | Hyderabad News
Hyderabad: The US Food and Drug Administration has approved Dr Reddy’s Laboratories’ rituximab biosimilar for the US market, the Hyderabad-based drug maker said on Saturday. The product is a biosimilar to Rituxan, a widely used monoclonal antibody therapy.Dr Reddy’s developed, manufactured and submitted the product for approval. The decision followed a recent FDA pre-license inspection…